RAPT Therapeutics (RAPT) Invested Capital: 2020-2024
Historic Invested Capital for Therapeutics (RAPT) over the last 5 years, with Sep 2024 value amounting to $95.5 million.
- Therapeutics' Invested Capital fell 44.73% to $95.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $95.5 million, marking a year-over-year decrease of 44.73%. This contributed to the annual value of $147.0 million for FY2023, which is 40.03% down from last year.
- Latest data reveals that Therapeutics reported Invested Capital of $95.5 million as of Q3 2024, which was down 12.56% from $109.2 million recorded in Q2 2024.
- In the past 5 years, Therapeutics' Invested Capital ranged from a high of $245.2 million in Q4 2022 and a low of $91.6 million during Q1 2021.
- In the last 3 years, Therapeutics' Invested Capital had a median value of $172.8 million in 2023 and averaged $170.9 million.
- Its Invested Capital has fluctuated over the past 5 years, first spiked by 83.44% in 2021, then slumped by 45.30% in 2024.
- Over the past 5 years, Therapeutics' Invested Capital (Quarterly) stood at $104.2 million in 2020, then skyrocketed by 78.90% to $186.4 million in 2021, then skyrocketed by 31.54% to $245.2 million in 2022, then tumbled by 40.03% to $147.0 million in 2023, then crashed by 44.73% to $95.5 million in 2024.
- Its last three reported values are $95.5 million in Q3 2024, $109.2 million for Q2 2024, and $130.8 million during Q1 2024.